Floatz logo

Ramosetron

Breast Cancer Female

Pusan National University HospitalSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
89/ 100

Competitive context

891 Active assets in the Breast Cancer Female cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Palbociclib
Hoffmann-La Roche
Phase 4BB
Loratadine
Noha Mansour
Phase 2BB

View all 50 →

Same molecule, other indications

Ramosetron is also rated in:

Uterine Myoma, Ovary Neoplasm, AdenomyosisDormant
B
Indicative ·
60 / 100
View asset →
chemotherapy-induced toxicityDormant
B
Indicative ·
57 / 100
View asset →
post-operative pain, non-human animalDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →